Progyny (NASDAQ:PGNY) Stock Gets Price Target Increase from Citizens Jmp

Progyny (NASDAQ:PGNY) had its target price boosted by equities researchers at Citizens Jmp from $33.00 to $38.00 in a note issued to investors on Thursday, Benzinga reports. The brokerage presently has a “market outperform” rating on the stock. Citizens Jmp‘s target price indicates a potential upside of 9.07% from the company’s previous close.

Several other equities research analysts have also recently weighed in on PGNY. Wells Fargo & Company upped their price target on shares of Progyny from $37.00 to $38.00 and gave the stock an “overweight” rating in a research report on Thursday. Weiss Ratings raised shares of Progyny from a “hold (c)” rating to a “hold (c+)” rating in a report on Thursday, October 8th. Zacks Research downgraded shares of Progyny from a “strong-buy” rating to a “hold” rating in a research note on Monday, October 19th. Leerink Partners set a $38.00 price objective on shares of Progyny in a research note on Wednesday, July 22nd. Finally, KeyCorp upped their target price on Progyny from $30.00 to $35.00 and gave the stock an “overweight” rating in a report on Monday, July 13th. Eleven equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $34.92.

Progyny Stock Performance

NASDAQ PGNY traded up $0.47 on Thursday, reaching $34.84. 1,548,505 shares of the stock traded hands, compared to its average volume of 956,940. Progyny has a 12 month low of $16.10 and a 12 month high of $35.50. The company has a market cap of $2.67 billion, a price-to-earnings ratio of 31.96, a PEG ratio of 2.03 and a beta of 0.97. The company has a fifty day moving average price of $27.45 and a 200-day moving average price of $24.59.

Progyny (NASDAQ:PGNY) last posted its quarterly earnings results on Wednesday, November 4th. The company reported $0.52 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.31 by $0.21. The business had revenue of $341.25 million for the quarter, compared to the consensus estimate of $340.76 million. Progyny had a return on equity of 15.98% and a net margin of 6.00%. The business’s revenue was up 8.9% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.15 EPS. As a group, research analysts anticipate that Progyny will post 1.25 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Progyny news, Director Kevin K. Gordon sold 11,500 shares of the stock in a transaction dated Thursday, September 10th. The stock was sold at an average price of $27.94, for a total value of $321,310.00. Following the completion of the sale, the director directly owned 6,792 shares in the company, valued at approximately $189,768.48. This trade represents a 62.87% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, COO Melissa B. Cummings sold 1,879 shares of the stock in a transaction dated Wednesday, October 14th. The shares were sold at an average price of $28.00, for a total value of $52,612.00. Following the completion of the sale, the chief operating officer owned 66,496 shares of the company’s stock, valued at approximately $1,861,888. This trade represents a 2.75% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 19,421 shares of company stock valued at $539,960 in the last 90 days. Corporate insiders own 9.90% of the company’s stock.

Institutional Investors Weigh In On Progyny

A number of large investors have recently modified their holdings of the business. Public Employees Retirement System of Ohio purchased a new position in shares of Progyny in the 2nd quarter valued at approximately $29,000. Nykredit A S purchased a new stake in Progyny during the 2nd quarter worth approximately $38,000. IFP Advisors Inc grew its position in Progyny by 376.0% during the 2nd quarter. IFP Advisors Inc now owns 1,961 shares of the company’s stock worth $57,000 after purchasing an additional 1,549 shares during the last quarter. Toth Financial Advisory Corp acquired a new position in Progyny during the 2nd quarter valued at approximately $65,000. Finally, Integrated Wealth Concepts LLC purchased a new position in shares of Progyny in the second quarter worth $74,000. Hedge funds and other institutional investors own 94.93% of the company’s stock.

Trending Headlines about Progyny

Here are the key news stories impacting Progyny this week:

• Positive Sentiment: Progyny reported third-quarter earnings of $0.52 per share and revenue of $341.25 million, slightly above the cited consensus revenue estimate. Revenue grew 8.9% year over year, while earnings increased from $0.15 per share a year earlier. Read More.
• Positive Sentiment: The company raised its full-year 2026 earnings guidance, a sign that management sees stronger earnings prospects. Read More.
• Positive Sentiment: Several analysts raised their price targets following the results: Citizens JMP and Leerink Partners moved to $38, while Cantor Fitzgerald raised its target to $35 and maintained an overweight rating. These revisions reinforce a favorable analyst view, although the targets imply varying degrees of potential upside. Read More.
• Neutral Sentiment: Coverage highlighted new client wins and margin expansion, but also noted a cautious market response. This suggests investors may be weighing growth and profitability improvements against expectations already reflected in the stock. Read More.

Progyny Company Profile

Progyny, Inc is a benefits-management company focused on fertility and family-building care. The company works with employers to provide comprehensive benefits that help members access fertility treatments and related services through a network of specialized providers.

Its offerings include coverage and support for services such as in vitro fertilization, fertility testing, egg and sperm freezing, donor services, gestational surrogacy, and adoption. Progyny also provides pharmacy benefits through Progyny Rx, as well as personalized guidance intended to help members navigate treatment options, providers, and the broader family-building process.

Progyny primarily serves self-insured employers and their employees in the United States.